SGLT2 inhibitors represent one of the most remarkable therapeutic developments in heart failure care, transitioning from ...

Patients with AAV and kidney involvement who take SGLT-2 inhibitors may have a reduced risk for ESRD and kidney transplant ...

In a recent study published in the European Heart Journal, researchers assessed the impact of sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors on type 2 diabetes and heart failure (HF) ...

Three popular GLP-1 receptor agonists carried similar risks for serious gastrointestinal (GI) events among adults with type 2 ...

CHICAGO -- SGLT2 inhibitor use was linked to reduced progression of in-situ pulmonary adenocarcinoma, an observational study showed. Nodule growth over the median 28 months of follow-up was 62% less ...

The final thesis of Professor Lim Soo's team of the Department of Endocrine Metabolism at Bundang Seoul National University ...

SAN DIEGO -- Benefits with empagliflozin (Jardiance) for cardiovascular and renal health linger for about a year after discontinuation, as off-drug follow-up from the EMPA-KIDNEY trial showed. During ...

When canagliflozin (Invokana) was approved in 2013, the SGLT2 inhibitor was touted as a first in a new medication class that was, at the time, the only oral, once-daily medication to reduce blood ...

Real-world data reinforce SGLT2 inhibitors as first-line therapy for frail, older adults with heart failure with preserved ...

SGLT-2 inhibitors were linked to lower risk for autoimmune rheumatic diseases in those with diabetes compared with sulfonylureas.

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Data derived from: D ...